Loss of exclusivity on several brands hurts AstraZeneca in Q1

Revenue contracted 12 per cent to 6.39bn dollar in the first quarter at FTSE 100-listed pharmaceuticals group AstraZeneca after losses of exclusivity for Seroquel IR and Atacand in many markets, and for Crestor in Canada.

Revenue contracted 12 per cent to 6.39bn dollar in the first quarter at FTSE 100-listed pharmaceuticals group AstraZeneca after losses of exclusivity for Seroquel IR and Atacand in many markets, and for Crestor in Canada.

The group reported that growth for Symbicort, Brilinta, Iressa and the inclusion of the Amylin diabetes products delivered more than $250m of revenue growth at constant exchange rates in the quarter.

Emerging Markets revenue increased by 9.0% at constant exchange rates (CER) in the quarter and core operating profit was down 21% at CER to $2.32bn in the first quarter.

The group said that the core operating profit decline had been driven by lower revenue and lower core other income, partially offset by core operating costs that were 4.0% lower at CER than last year.

Core earnings per share (EPS) was $1.41, down 21% at CER compared to the first quarter last year. This declined in line with core operating profit, as a higher tax rate this year was broadly offset by a lower number of shares outstanding and lower net finance expense, the group said.

AstraZeneca said that it continued to expect a mid-to-high single digit decline in revenue at CER and a core EPS decline that would be significantly larger than the decline in revenue for the full year.

Pascal Soriot, Chief Executive Officer of AstraZeneca, commented: "As anticipated, the first-quarter performance reflects the loss of exclusivity for several large products. We remain focused on our strategic priorities of returning to growth and achieving scientific leadership."

Soriot added: "Brilinta, the diabetes franchise, Emerging Markets, Japan and our Respiratory products have all made good progress and we continued to invest in distinctive science that will advance our knowledge of disease physiology and help to identify new drug targets."

MF

Recommended

Improve your odds of investment success with these three stocks
Share tips

Improve your odds of investment success with these three stocks

Professional investor Tom Wildgoose of the Nomura Global High Conviction Fund highlights three of his favourite stocks.
2 Aug 2021
How to profit from pampered pets beyond the pandemic
Share tips

How to profit from pampered pets beyond the pandemic

Covid-19 has greatly boosted ownership. But the market had been expanding for years, and demographic, cultural and medical trends all point to long-te…
30 Jul 2021
Share tips of the week – 30 July
Share tips

Share tips of the week – 30 July

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
30 Jul 2021
Robinhood is going public – should you invest?
US stockmarkets

Robinhood is going public – should you invest?

Online stockbroking app Robinhood is going public on the US stock exchange. Saloni Sardana looks at whether it's worth a punt.
29 Jul 2021

Most Popular

Why the UK's 2.5% inflation is a big deal
Inflation

Why the UK's 2.5% inflation is a big deal

After years of inflation being a financial-assets problem, it is now an “ordinary things” problem too, says Merryn Somerset Webb. But central banks st…
16 Jul 2021
The MoneyWeek Podcast: Asia, financial repression and the nature of capitalism
Economy

The MoneyWeek Podcast: Asia, financial repression and the nature of capitalism

Russell Napier talks to Merryn about financial repression – or "stealing money from old people slowly" – plus how Asian capitalism is taking over in t…
16 Jul 2021
Cryptocurrency roundup: Twitter founder’s “DeFi” platform
Bitcoin & crypto

Cryptocurrency roundup: Twitter founder’s “DeFi” platform

In crypto this week: regulators are getting worried; Jack Dorsey’s bitcoin DeFi platform; and dogecoin’s co-founder lambasts cryptocurrencies.  Salon…
16 Jul 2021